RESUMO
Cytotoxic T lymphocytes (CTLs) recognize peptides presented by HLA class I molecules on the cell surface. The C terminus of these CTL epitopes is considered to be produced by the proteasome. Here we demonstrate that the cytosolic endopeptidases nardilysin and thimet oligopeptidase (TOP) complemented proteasome activity. Nardilysin and TOP were required, either together or alone, for the generation of a tumor-specific CTL epitope from PRAME, an immunodominant CTL epitope from Epstein-Barr virus protein EBNA3C, and a clinically important epitope from the melanoma protein MART-1. TOP functioned as C-terminal trimming peptidase in antigen processing, and nardilysin contributed to both the C-terminal and N-terminal generation of CTL epitopes. By broadening the antigenic peptide repertoire, nardilysin and TOP strengthen the immune defense against intracellular pathogens and cancer.
Assuntos
Antígenos de Neoplasias/metabolismo , Epitopos de Linfócito T/metabolismo , Metaloendopeptidases/metabolismo , Linfócitos T Citotóxicos/metabolismo , Apresentação de Antígeno/genética , Antígenos de Neoplasias/química , Antígenos de Neoplasias/imunologia , Citotoxicidade Imunológica/genética , Epitopos de Linfócito T/química , Epitopos de Linfócito T/imunologia , Antígeno HLA-A3/metabolismo , Humanos , Células K562 , Metaloendopeptidases/genética , Metaloendopeptidases/imunologia , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/imunologia , Fragmentos de Peptídeos/metabolismo , Complexo de Endopeptidases do Proteassoma/metabolismo , Ligação Proteica , RNA Interferente Pequeno/genética , Linfócitos T Citotóxicos/imunologia , Linfócitos T Citotóxicos/patologia , Transgenes/genéticaRESUMO
Recent data suggest that HLA epitope matching is beneficial for the prevention of de novo donor specific antibody (DSA) formation after transplantation. In this review, different approaches to predict the immunogenicity of an HLA mismatch will be discussed. The parameters used in these models are often called epitopes but the actual antibody epitope is far more complex. Exact knowledge of the antibody epitope is crucial if epitope matching is also used as a tool to select compatible donors for (highly) sensitized patients. Evidence is provided that it is not always possible to give an exact definition of an antibody epitope. We conclude that HLA "epitope" matching is superior over HLA antigen matching with respect to the prevention of de novo DSA formation and will enhance the prediction of acceptable HLA mismatches for sensitized patients. However, epitope matching at our current level of knowledge will not solve all histocompatibility problems as unexpected antibody reactivity still may occur.
Assuntos
Epitopos/química , Teste de Histocompatibilidade/métodos , Isoanticorpos/imunologia , Alelos , Formação de Anticorpos , Europa (Continente) , Rejeição de Enxerto/imunologia , Antígenos HLA/imunologia , Antígenos de Histocompatibilidade/imunologia , Humanos , Imunoglobulina G/imunologia , Transplante de Rim , Reoperação , Doadores de Tecidos , Obtenção de Tecidos e Órgãos , Listas de EsperaRESUMO
BACKGROUND: Once a patient has produced a red blood cell (RBC) antibody, there is an increased risk of additional antibody formation after subsequent RBC exposure. Recently, we observed that HLA-DRB1*15 was overrepresented in 379 multiple RBC antibody responders compared to controls or 562 patients with a single RBC antibody (odds ratio [OR], 1.7; 95% confidence interval [CI], 1.3-2.3). In this study we evaluated whether the HLA-DRB1*15 represents a responder phenotype against HLA and/or RBC antigens. STUDY DESIGN AND METHODS: HLA-DRB1*15 frequencies in single and multiple antibody responders were compared between three groups of individuals: 1) those with HLA antibodies, 2) those with RBC antibodies, and 3) those with both RBC and HLA antibodies. RESULTS: A total of 3959 immunized patients (female-to-male ratio, 2.3) had been HLA-DRB1 typed. Among the 3275 individuals with HLA antibodies, the frequency of the DRB1*15 phenotype differed significantly from 19.7% in patients with a panel reactivity (PRA) of not more than 20% to 26.9% in patients with PRA of more than 80% (OR, 1.5; 95% CI, 1.2-1.9). This association between DRB1*15 and multiresponsiveness was mainly due to pregnancy-induced HLA immunization. In the 257 individuals with RBC and HLA antibodies, the frequency of DRB1*15 was 4.2 times (95% CI, 1.1-16) higher in those with multiple RBC antibodies and HLA-PRA of more than 50% compared to only single RBC responders with PRA of less than 20%. CONCLUSION: The HLA-DRB1*15 phenotype is associated with broad RBC and HLA immunization.
Assuntos
Eritrócitos/imunologia , Antígenos HLA/imunologia , Cadeias HLA-DRB1/imunologia , Anticorpos , Feminino , Humanos , Masculino , Fenótipo , Gravidez , Estudos RetrospectivosRESUMO
Red blood cell (RBC) antibodies can persist for decades or decrease quickly to undetectable levels. Antibody persistence has not been systematically studied. Women whose children are treated with intrauterine transfusions (IUT) for haemolytic disease of the fetus (HDFN) often produce additional antibodies, which can be evoked by the intrauterine transfusion or by fetomaternal haemorrhage during the procedure. Factors associated with persistence of both the antibodies responsible for HDFN and additional antibodies were studied in 260 women whose children were treated with IUT between 1988 and 2008. They possessed 499 (205 anti-D and 294 non-D) antibodies after the last IUT. After a median follow-up of 8·7 years, all 260 antibodies primarily responsible for HDFN had persisted. Additional antibodies directed against antigens of the children persisted in 70·6%, and in 32·3% if they were not child-specific (P < 0·001). Antibodies induced by irradiated IUT persisted in only 7·1%. Multivariate analyses showed that non-HDFN antibody persistence was dependent on the antibody titre and specificity. In conclusion, persistence of antibodies mainly depends on antibody strength and specificity. Difference between fetal or non-fetal immunogens suggests maintenance of antigenic stimulation possibly by long-term fetomaternal chimerism.
Assuntos
Transfusão de Sangue Intrauterina , Eritroblastose Fetal/terapia , Eritrócitos/imunologia , Isoanticorpos/sangue , Adolescente , Adulto , Criança , Pré-Escolar , Quimerismo , Feminino , Seguimentos , Humanos , Lactente , Recém-Nascido , Isoantígenos/sangue , Pessoa de Meia-Idade , Gravidez , Imunoglobulina rho(D) , Adulto JovemRESUMO
BACKGROUND: A minority of red blood cell (RBC) alloantigen-exposed persons form antibodies. Responders are at high risk of developing additional antibodies upon subsequent transfusions. Several studies showed an association between particular HLA-DRB1 phenotypes and the development of specific RBC antibodies. This study evaluates the presence of HLA-DRB1 antigens in individuals with single or multiple RBC antibody specificities to explore whether the response against RBC antigens is associated with a summation of particular HLA-DRB1 susceptibility antigens. STUDY DESIGN AND METHODS: Frequencies of HLA-DRB1 alleles in individuals with antibodies against clinically relevant antigens were compared to a large population cohort to calculate odds ratios (ORs) for alloimmunization to different RBC antigens. RESULTS: The study cohort consisted of 941 individuals (female-to-male ratio, 3.8) possessing 1462 antibody specificities elicited by transfusion, pregnancy, transplantation, or a combination of these. Besides confirmation of known associations, new associations were identified for anti-E with DRB1*09 and for anti-S with DRB1*07 (ORs, 3.7 and 8.7, respectively). Multiple antibody formation was in a minority of cases associated with the presence of multiple DRB1 susceptibility genes. In multiple responders DRB1*15 was present in almost 40% of cases compared to approximately 25% in single-antibody responders and in the control population. CONCLUSION: This study suggests that HLA-DRB1 restriction plays an important role for a first RBC antibody response but multiple antibody formation seems less dependent on the presence of particular HLA restriction genes, while HLA-DRB1*15 may represent a susceptibility phenotype enhancing formation of multiple RBC antibody specificities.
Assuntos
Antígenos de Grupos Sanguíneos/imunologia , Eritrócitos/imunologia , Cadeias HLA-DRB1/análise , Imunização , Isoanticorpos/sangue , Isoantígenos/imunologia , Incompatibilidade de Grupos Sanguíneos/etiologia , Incompatibilidade de Grupos Sanguíneos/genética , Incompatibilidade de Grupos Sanguíneos/imunologia , Tipagem e Reações Cruzadas Sanguíneas , Transfusão de Sangue , Suscetibilidade a Doenças , Feminino , Frequência do Gene , Genes MHC da Classe II , Cadeias HLA-DRB1/genética , Teste de Histocompatibilidade , Humanos , Masculino , Razão de Chances , Gravidez , Imunologia de TransplantesRESUMO
Human leukocyte antigen alloantibodies have a multitude of damaging effects on the allograft, both complement (C') activation and Fc-independent ones. To date, the clinical significance of non-C' fixing (NCF) HLA donor-specific antibodies (DSA) is still unclear. In this study, we investigated whether renal transplant recipients with NCF-DSA subclasses (IgG2/IgG4, IgA1/IgA2) are at higher risk of graft loss compared to patients with exclusively C' fixing (IgG1/IgG3). Blood samples from 274 patients were analyzed for HLA IgG and IgA subclasses using a modified single-antigen bead assay. We identified 50 (18.2%) patients with circulating NCF antibodies either DSA (n=17) or against third-party HLA (n=33). NCF-DSAs were preferentially of IgG2/IgG4 isotype (11/17) and were mainly directed against HLA class II (13/17). NCF DSA were present as a mixture with strong C' fixing IgG1/IgG3. Graft survival was similar between patients with exclusively C' fixing antibodies and those with a mixture panel (log rang test P=0.162), and also among patients with different immunoglobulin isotype and subclasses (long-rank test, P=0.732). We conclude that expansion of DSA to NCF subclasses postrenal transplantation does not seem to be associated with worse graft survival as compared to the presence of exclusive C' fixing subclasses.
Assuntos
Antígenos HLA/imunologia , Isoanticorpos/sangue , Transplante de Rim , Doadores de Tecidos , Adulto , Especificidade de Anticorpos , Ativação do Complemento , Feminino , Sobrevivência de Enxerto/imunologia , Humanos , Switching de Imunoglobulina , Imunoglobulina G/sangue , Imunoglobulina G/classificação , Isoanticorpos/classificação , Estimativa de Kaplan-Meier , Transplante de Rim/efeitos adversos , Masculino , Pessoa de Meia-Idade , Modelos de Riscos Proporcionais , Fatores de Risco , Imunologia de TransplantesRESUMO
Viral infection is a major cause of morbidity and mortality, and there are few therapeutic options available to augment a virus-specific T cell response. Although allo-HLA cross-reactivity from virus-specific memory T cells is common, it is unclear whether priming with specific allogeneic cells could conversely elicit a viral peptide/self-HLA restricted cytotoxic T cell response in humans. First, we used the previously described allo-HLA-B*44:02 cross-reactivity of EBV peptide/HLA-B8 restricted T cells, to determine whether allogeneic HLA stimulation can elicit a cytolytic immune response against EBV. HLA-B8(+) HLA-B44(-) EBV-seropositive PBMCs were stimulated with either HLA-B*44:02(+) or HLA-B*44:03(+) mismatched irradiated PBMCs in a 7-10 d MLR. The allo-HLA stimulated responder cells were then evaluated for cytotoxicity using EBV peptide loaded autologous target cells and unloaded HLA-B8(+) EBV LCL target cells. PBMCs from EBV-seropositive donors gained EBV-specific cytolytic effector function following specific allo-HLA stimulation. Finally, we also elicited cytolytic CMV-specific responses using specific allogeneic cell stimulation, to confirm that this technique can be used to elicit viral peptide/self-HLA restricted responses even from nonpublic TCR responses. Allogeneic cell stimulation used as a cell therapy may be a potential tool to augment an antiviral T cell response in patients with EBV or CMV infection.
Assuntos
Infecções por Citomegalovirus/imunologia , Citomegalovirus/imunologia , Infecções por Vírus Epstein-Barr/imunologia , Antígenos HLA-B/imunologia , Herpesvirus Humano 4/imunologia , Memória Imunológica , Linfócitos T Citotóxicos/imunologia , Células Cultivadas , Feminino , Humanos , Masculino , Peptídeos/imunologia , Proteínas Virais/imunologiaRESUMO
BACKGROUND: Women whose fetuses were treated with intrauterine transfusions (IUTs) for alloimmune hemolytic disease are high responders to red blood cell (RBC) antigens. We investigated the risk for HLA alloimmunization. STUDY DESIGN AND METHODS: Women and their children treated with IUT between 1987 and 2008 were included. Participants were HLA antigen typed and studied for the prevalence of HLA antibodies compared to age-matched parous nontransfused blood donors. Anti-D titer, the formation of new RBC antibodies after IUT, and the degree of fetomaternal HLA mismatches on HLA antibody formation and/or persistence were analyzed. RESULTS: A higher prevalence of HLA Class I antibodies was observed in these women compared to controls (41% vs. 23%). Both a higher anti-D titer (>8000) and formation of new RBC antibodies after IUT were associated with increased HLA immunization. HLA antibody formation was associated with the number of fetomaternal triplet epitope mismatches. Antigens within HLA-Bw4, HLA-B35/51/52/53/18/78-complex and A1/A9, were higher and mismatches within HLA-C were less immunogenic than expected. HLA antibodies against the IUT-treated fetus were more persistent than other antibodies. CONCLUSION: Women whose fetuses were treated with IUT had a high risk of developing and maintain fetal-specific HLA Class I antibodies. Factors associated with increased HLA immunization were a higher amount of fetomaternal HLA triplet mismatches, higher anti-D titer, and additional RBC antibody formation. We presume that the induction of HLA Class I antibodies is the result of increased fetomaternal hemorrhage during IUT, eliciting antibodies in women with an increased susceptibility to alloimmunization.
Assuntos
Antígenos de Grupos Sanguíneos/imunologia , Transfusão de Sangue Intrauterina/efeitos adversos , Eritroblastose Fetal/terapia , Antígenos HLA/imunologia , Isoanticorpos/sangue , Adolescente , Adulto , Biomarcadores/sangue , Incompatibilidade de Grupos Sanguíneos/etiologia , Incompatibilidade de Grupos Sanguíneos/imunologia , Estudos de Casos e Controles , Ensaio de Imunoadsorção Enzimática , Eritroblastose Fetal/imunologia , Feminino , Seguimentos , Humanos , Modelos Logísticos , Pessoa de Meia-Idade , Análise Multivariada , Razão de Chances , Gravidez , Sistema do Grupo Sanguíneo Rh-Hr/imunologia , Índice de Gravidade de Doença , Adulto JovemRESUMO
In the absence of treatment, most HIV-1-infected humans develop AIDS. However, a minority are long-term nonprogressors, and resistance is associated with the presence of particular HLA-B*27/B*57 molecules. In contrast, most HIV-1-infected chimpanzees do not contract AIDS. In comparison with humans, chimpanzees experienced an ancient selective sweep affecting the MHC class I repertoire. We have determined the peptide-binding properties of frequent chimpanzee MHC class I molecules, and show that, like HLA-B*27/B*57, they target similar conserved areas of HIV-1/SIV(cpz). In addition, many animals appear to possess multiple molecules targeting various conserved areas of the HIV-1/SIV(cpz) Gag protein, a quantitative aspect of the immune response that may further minimize the chance of viral escape. The functional characteristics of the contemporary chimpanzee MHC repertoire suggest that the selective sweep was caused by a lentiviral pandemic.
Assuntos
Síndrome da Imunodeficiência Adquirida/prevenção & controle , HIV-1/genética , HIV-1/imunologia , Antígenos HLA-B/genética , Antígeno HLA-B27/genética , Antígenos de Histocompatibilidade Classe I/genética , Pan troglodytes/genética , Pan troglodytes/imunologia , Vírus da Imunodeficiência Símia/genética , Vírus da Imunodeficiência Símia/imunologia , Síndrome da Imunodeficiência Adquirida/genética , Síndrome da Imunodeficiência Adquirida/imunologia , Sequência de Aminoácidos , Animais , Linhagem Celular , Sequência Conservada , Produtos do Gene gag/genética , Produtos do Gene gag/metabolismo , Genes MHC Classe I , Sobreviventes de Longo Prazo ao HIV , Humanos , Dados de Sequência Molecular , Ligação Proteica , Especificidade da Espécie , Linfócitos T Citotóxicos/imunologiaRESUMO
Graft-versus-host disease and graft rejection are major complications of allogeneic HLA-mismatched stem cell transplantation or organ transplantation that are caused by alloreactive T cells. Because a range of acute viral infections have been linked to initiating these complications, we hypothesized that the cross-reactive potential of virus-specific memory T cells to allogeneic (allo) HLA molecules may be able to mediate these complications. To analyze the allo-HLA reactivity, T cells specific for Epstein-Barr virus, cytomegalovirus, varicella zoster virus, and influenza virus were tested against a panel of HLA-typed target cells, and target cells transduced with single HLA molecules. Eighty percent of T-cell lines and 45% of virus-specific T-cell clones were shown to cross-react against allo-HLA molecules. The cross-reactivity of the CD8 and CD4 T-cell clones was directed primarily against HLA class I and II, respectively. However, a restricted number of CD8 T cells exhibited cross-reactivity to HLA class II. T-cell receptor (TCR) gene transfer confirmed that allo-HLA reactivity and virus specificity were mediated via the same TCR. These results demonstrate that a substantial proportion of virus-specific T cells exert allo-HLA reactivity, which may have important clinical implications in transplantation settings as well as adoptive transfer of third-party virus-specific T cells.
Assuntos
Antígenos HLA/imunologia , Memória Imunológica/imunologia , Linfócitos T/imunologia , Linfócitos T/virologia , Vírus/imunologia , Linhagem Celular , Células Clonais , Citotoxicidade Imunológica , Herpesvirus Humano 4/imunologia , Humanos , Subpopulações de Linfócitos/imunologia , Subpopulações de Linfócitos/virologia , Receptores de Antígenos de Linfócitos T/imunologia , Especificidade da Espécie , Transplante HomólogoRESUMO
The introduction of new sensitive assays for the detection of HLA antibodies on basis of their binding to isolated HLA molecules has got an enormous impact on the decision-making process with respect to donor selection for sensitized patients. In the past, when only complement-dependent cytotoxicity was used as a tool to define HLA alloantibodies, the presence of donor specific antibodies (DSA) before transplantation was considered a contraindication for renal transplantation with that donor. The interpretation of the current DSA results is far more difficult and leads to a lot of discussions and controversy. The problems associated with the use of solid phase assays for clinical decision making and possible solutions are discussed.
Assuntos
Rejeição de Enxerto/imunologia , Antígenos HLA/imunologia , Isoanticorpos/sangue , Transplante de Rim/imunologia , Biomarcadores/sangue , Contraindicações , Ensaio de Imunoadsorção Enzimática , Rejeição de Enxerto/sangue , Rejeição de Enxerto/prevenção & controle , Humanos , Testes Imunológicos , Isoanticorpos/imunologia , Medição de Risco , Fatores de RiscoRESUMO
BACKGROUND: The Leiden University Medical Center (LUMC) is the Dutch national referral centre for pregnancies complicated by haemolytic disease of the fetus and newborn (HDFN) caused by maternal alloimmunization. Yearly, 20-25 affected fetuses with severe anaemia are transfused with intra-uterine blood transfusions (IUT). Mothers of whom their fetus has undergone IUT for HDFN are considered high responders with regard to red blood cell (RBC) antibody formation. Most study groups report high perinatal survival, resulting in a shift in attention towards short- and long-term outcome in surviving children. METHODS/DESIGN: We set up a large long-term observational follow-up study (LOTUS study), in cooperation with the Sanquin Blood Supply Foundation and the LUMC departments of Obstetrics, Neonatology and ImmunoHematology & Bloodtransfusion.The first part of this study addresses several putative mechanisms associated with blood group alloimmunization in these mothers. The second part of this study determines the incidence of long-term neurodevelopment impairment (NDI) and associated risk factors in children treated with IUT. All women and their life offspring who have been treated with IUT for HDFN in the LUMC from 1987-2008 are invited to participate and after consent, blood or saliva samples are taken. RBC and HLA antigen profile and antibodies are determined by serologic or molecular techniques. Microchimerism populations are tested by real time polymerase chain reaction (RT PCR).All children are tested for their neurological, cognitive and psychosocial development using standardised tests and questionnaires. The primary outcome is neurodevelopmental impairment (NDI), a composite outcome defined as any of the following: cerebral palsy, cognitive or psychomotor development < 2 standard deviation, bilateral blindness and/or bilateral deafness. DISCUSSION: The LOTUS study includes the largest cohort of IUT patients ever studied and is the first to investigate post-IUT long-term effects in both mother and child. The results may lead to a change in transfusion policy, in particular future avoidance of certain incompatibilities. Additionally the LOTUS study will provide clinicians and parents better insights in the long-term neurodevelopmental outcome in children with HDFN treated with IUTs, and may improve the quality of antenatal counselling and long-term guidance.
Assuntos
Cegueira/epidemiologia , Transfusão de Sangue Intrauterina/efeitos adversos , Paralisia Cerebral/epidemiologia , Transtornos Cognitivos/epidemiologia , Surdez/epidemiologia , Eritroblastose Fetal/terapia , Transtornos Psicomotores/epidemiologia , Adolescente , Adulto , Cegueira/etiologia , Paralisia Cerebral/etiologia , Criança , Pré-Escolar , Transtornos Cognitivos/etiologia , Estudos de Coortes , Surdez/etiologia , Feminino , Seguimentos , Humanos , Gravidez , Transtornos Psicomotores/etiologia , Projetos de Pesquisa , Tempo , Resultado do Tratamento , Adulto JovemRESUMO
PURPOSE OF REVIEW: Highly sensitized patients on the kidney waitlist have the least chance to receive a cross-match negative offer and, once transplanted, have a lower patient and graft survival. Until recently, complement-dependent cytotoxicity (CDC) was the standard method to define if a patient is sensitized or not. The introduction of more sensitive solid-phase assays (SPAs) to detect human leukocyte antigen (HLA) antibodies has led to a dramatic increase in the number of the patients on the waitlist. This review advocates the use of the 'old-fashioned' CDC to define the degree of sensitization and as the tool for allocation of kidneys to highly sensitized patients. RECENT FINDINGS: HLA-antibody screening using CDC is a cumbersome method that needs a high degree of expertise. SPA is easier, more reproducible and accessible to a large number of laboratories. The dogma that donor-specific antibodies (DSAs) are a contraindication for transplantation disappeared. The presence of SPA-DSA is rather a risk factor for complications than a contraindication. The opinion on the clinical relevance of SPA-DSA differs between the centers. SUMMARY: A proper designation of highly sensitized patients is crucial since it impacts the allocation. CDC-DSA is generally considered a contraindication for transplantation, whereas SPA-DSA remains controversial. The lack of consensus between centers is partly due to the heterogeneity of the HLA antibodies involved, the lack of standardization in antibody titer, the immunoglobulin (sub)class and the epitopes recognized. Until the issues are resolved, one should be careful to use the information generated in SPA for the allocation of kidneys and focus on the 'old CDC' that has shown to be effective in the past.
Assuntos
Testes Imunológicos de Citotoxicidade , Antígenos HLA/imunologia , Teste de Histocompatibilidade/métodos , Transplante de Rim , Proteínas do Sistema Complemento/imunologia , Rejeição de Enxerto/imunologia , Sobrevivência de Enxerto/imunologia , Humanos , Isoanticorpos/imunologiaRESUMO
OBJECTIVE: Coeliac disease (CD) is associated with HLA-DQ2 and DQ8. The clinical picture is variable and certain human leucocyte antigen (HLA) DQ/DR combinations have a higher relative risk (RR) for CD than others. Moreover, the HLA-DQ gene-dose effect has an impact on the strength of the gluten-specific T-cell response and thus may correlate with clinical presentation and severity of CD. The aim of this study was to determine the correlation between HLA-DQ/DR-based genotypes and the variation in phenotypes of the disease. MATERIAL AND METHODS: A total of 113 non-related Caucasian children clinically diagnosed with CD during the period 1980-2003 with a known HLA type were included in the study. Patients were divided into four categories according to amount of disease expression predisposing to HLA-DQ2 or HLA-DQ8 molecules and the known RR of their HLA-DR/DQ type for CD: high (DR3DQ2 homozygous and DR3DQ2/DR7DQ2), substantial (DR3DQ2/DR5DQ7 and DR5DQ7/DR7DQ2), moderate (DR3DQ2-DR4DQ8 and DR3DQ2/DR*DQ*) and low (DR7DQ2/DR*DQ*, DR4DQ8- DR*DQ* and DR*DQ*- DR*DQ*). The clinical data and HLA genotypes of these patients were compared. RESULTS: The 113 children were diagnosed with CD at a mean age of 4.6 years and boys were significantly older than girls when diagnosed (p=0.01). RR for having CD was highest for the high HLA-risk group (RR 8.1). With the exception of a greater frequency of abdominal distension and fewer non-gastrointestinal symptoms in the substantial HLA-risk group, there were no significant differences in clinical characteristics or degree of severity of the small-bowel histological findings between the children in the different HLA-risk groups. CONCLUSION: No correlation was found between disease severity and a double HLA-DQ2 gene dose.
Assuntos
Doença Celíaca/genética , Antígenos HLA-DQ/genética , Antígeno HLA-DR3/genética , Doença Celíaca/diagnóstico , Doença Celíaca/imunologia , Criança , Pré-Escolar , Feminino , Predisposição Genética para Doença , Genótipo , Glutens/imunologia , Antígenos HLA-DQ/imunologia , Antígenos HLA-DR/genética , Antígeno HLA-DR3/imunologia , Humanos , Masculino , Programas de Rastreamento , Fenótipo , Estudos Retrospectivos , Índice de Gravidade de Doença , Linfócitos T/imunologiaRESUMO
PURPOSE OF REVIEW: Here, we elaborate on one of the challenges in the current era of organ transplantation: to offer suitable organs to highly sensitized patients. Desensitization protocols and the use of an acceptable mismatch program are discussed. RECENT FINDINGS: New protocols have been proposed for highly sensitized patients by using, in addition to intravenous immunoglobulin, an anti-CD20 monoclonal antibody (rituximab). The results look very promising for the short-term outcome. The long-term data are still pending. A new 'old' drug is proposed for elimination of the antibody-producing plasma cells, bortezomib, and may serve as a useful addition to the current protocols. The chances of highly sensitized patients to receive a crossmatch negative organ via the acceptable mismatch program can be calculated (http://etrl.eurotransplant.nl/cms/index.php) allowing, in case of a very low probability, for an offer to enroll the patient at an early stage in a desensitization protocol. SUMMARY: The short- and long-term graft survival of highly sensitized patients transplanted via the Acceptable Mismatch protocol are excellent but, unfortunately, not all patients can be transplanted via this approach. Especially for these patients, desensitization therapies are the only solution. A comprehensive use of both alternatives, desensitization and acceptable mismatch program, seems to be the good way to go.
Assuntos
Dessensibilização Imunológica , Teste de Histocompatibilidade , Histocompatibilidade , Transplante de Órgãos , Seleção de Pacientes , Doadores de Tecidos , Obtenção de Tecidos e Órgãos , Anticorpos/sangue , Rejeição de Enxerto/imunologia , Rejeição de Enxerto/prevenção & controle , Sobrevivência de Enxerto , Antígenos HLA/imunologia , Humanos , Transplante de Órgãos/efeitos adversos , Medição de Risco , Fatores de Tempo , Resultado do Tratamento , Listas de EsperaRESUMO
In most primate species, the class II region of the Major Histocompatibility Complex (MHC) displays diversity with regard to gene copy number and combination of DRB genes present per region configuration. Some of these loci exhibit extremely high levels of allelic variability, whereas others display only moderate levels of polymorphism. To understand the evolutionary history of the various HLA-DR region genes, a large number of full-length sequences of rhesus macaques, chimpanzees and humans were determined. The exon-intron organisation of the DRA gene, displaying only low levels of polymorphism, appears to have been highly conserved during primate evolution. The physical length of various DRB genes/alleles, however, fluctuates significantly in primates due to the presence of indels (insertions/deletions), mainly mapping to intron 1. Phylogenetic evidence supports the notion that the generation of new DRB genes is a dynamic and steadily ongoing process. Indeed, most of the primate DRB alleles investigated represent relatively young entities, possessing species-unique sequences. This seems to contradict the current view that the highly similar peptide binding motifs of many HLA-, Patr- and Mamu-DR molecules, encoded by exon 2 of the DRB gene, represent old entities, which predate primate speciation. As no evidence was found for convergent evolution, the combination of these two observations indicates that ancient peptide binding motifs are frequently reshuffled among duplicated members of the HLA-DRB multigene family.
Assuntos
Antígenos HLA-DR/genética , Antígenos HLA-DR/metabolismo , Família Multigênica/genética , Peptídeos/metabolismo , Motivos de Aminoácidos , Animais , Sequência de Bases , Evolução Molecular , Éxons/genética , Antígenos HLA-DR/química , Humanos , Macaca/genética , Dados de Sequência Molecular , Pan troglodytes/genética , Filogenia , Polimorfismo Genético , Ligação Proteica , Seleção Genética , Alinhamento de Sequência , Homologia de Sequência do Ácido NucleicoRESUMO
Highly sensitized patients (anti-HLA) on the kidney waiting list wait longer for a suitable crossmatch negative organ. At the moment there are two strategies to enhance transplantation of these patients. One approach is the determination of acceptable HLA mismatches and application of this knowledge for the selection of crossmatch negative donors, and the second is the desensitization of patients with intravenous immunoglobulin-based protocols to enable transplantation of an organ from a donor towards which antibodies were originally present. Both approaches have advantages and disadvantages and are only successful in a proportion of the patients. The optimal solution is an integrated strategy whereby desensitization is used for those patients for whom the acceptable mismatch approach is not successful.
Assuntos
Terapia de Imunossupressão , Transplante de Rim/imunologia , Antígenos HLA/imunologia , Histocompatibilidade/imunologia , Teste de Histocompatibilidade , Humanos , Terapia de Imunossupressão/economia , Terapia de Imunossupressão/métodosRESUMO
BACKGROUND: The introduction of human leukocyte antigen (HLA)-matching in nonliving kidney transplantation has resulted into a better graft outcome, but also in an increase of waiting time, especially for patients with rare HLA phenotypes. We addressed the question of the differential influence of HLA-DR-matching versus HLA-A,B in clinical kidney transplantation. METHODS: We used Kaplan-Meier product limit method to estimate survival rates, and Cox proportional hazard regression for the estimation of relative risks (Hazard-ratios) for different variables. RESULTS: A single center study (n=456 transplants, performed between 1985 and 1999) showed that full HLA-DR compatibility leads to a lower incidence of biopsy confirmed acute rejections in the first 180 posttransplantation days. These results were substantiated using the Eurotransplant database (n=39,205 transplants performed between 1985 and 2005) where graft survival in the full HLA-DR compatible group was significantly better than in the incompatible. An additional positive effect of HLA-A,B matching was only found in the full HLA-DR compatible group. In both studies, the introduction of a single HLA-DR incompatibility eliminates the HLA-A,B matching effect. CONCLUSIONS: We propose to allocate postmortem kidneys only to patients with full HLA-DR compatibility, and use HLA-A,B compatibility as an additional selection criterion. All patients, irrespective of their ethnic origin, will profit since the polymorphism of HLA-DR is by far lower than that of HLA-A,B. Excessive kidney travel and cold ischemia time will be significantly reduced.
Assuntos
Antígenos HLA-DR/sangue , Alocação de Recursos para a Atenção à Saúde , Histocompatibilidade , Transplante de Rim , Doadores de Tecidos , Obtenção de Tecidos e Órgãos , Doença Aguda , Cadáver , Bases de Dados Factuais , Feminino , Rejeição de Enxerto/epidemiologia , Sobrevivência de Enxerto , Antígenos HLA-A/sangue , Antígenos HLA-B/sangue , Teste de Histocompatibilidade , Humanos , Incidência , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Modelos de Riscos Proporcionais , Risco , Fatores de TempoRESUMO
Non-classical Human Leukocyte Antigen (HLA)-E preferentially presents leader peptides derived from classical HLA-class I molecules. HLA-E can trigger opposed immune responses by interacting with inhibitory NKG2A or by activating NKG2C receptors on NK and T-cells. We studied the impact of HLA-E on renal allograft survival during acute cellular rejection. HLA-E expression was up-regulated in acute cellular rejection (ACR) biopsies (n=12) compared to biopsies from 13 renal allografts with no rejection-signs. HLA-E up-regulation was correlated with numbers of HLA-class I leader peptide mismatches (p=0.04). CD8+ and CD56+ infiltrating cells correlated with HLA-E expression (p<0.0001 and p=0.0009, respectively). Activating NKG2C receptor dominated on effector cells in biopsies and peripheral blood during ACR potentially allowing HLA-E-mediated immune activation. Moreover, HLA-E expression correlated with deterioration in renal allograft function (p<0.008) and reduced allograft survival (p=0.002). Our findings provide evidence that during renal allograft rejection HLA-E along with high numbers of mismatched HLA-class I leader peptides might represent additional targets for immune-activating responses.
Assuntos
Rejeição de Enxerto/imunologia , Sobrevivência de Enxerto/imunologia , Antígenos de Histocompatibilidade Classe I/imunologia , Transplante de Rim , Biomarcadores , Biópsia , Linfócitos T CD8-Positivos/imunologia , Linfócitos T CD8-Positivos/metabolismo , Feminino , Expressão Gênica , Rejeição de Enxerto/genética , Sobrevivência de Enxerto/genética , Antígenos de Histocompatibilidade Classe I/química , Antígenos de Histocompatibilidade Classe I/genética , Antígenos de Histocompatibilidade Classe I/metabolismo , Humanos , Imuno-Histoquímica , Rim/imunologia , Rim/metabolismo , Rim/patologia , Rim/fisiopatologia , Testes de Função Renal , Transplante de Rim/efeitos adversos , Contagem de Linfócitos , Masculino , Pessoa de Meia-Idade , Subfamília A de Receptores Semelhantes a Lectina de Células NK/metabolismo , Subfamília C de Receptores Semelhantes a Lectina de Células NK/metabolismo , Subpopulações de Linfócitos T/imunologia , Subpopulações de Linfócitos T/metabolismo , Transplante Homólogo , Antígenos HLA-ERESUMO
Cytomegalovirus (CMV)-based vaccines have shown remarkable efficacy in the rhesus macaque model of acquired immune deficiency syndrome, enabling 50% of vaccinated monkeys to clear a subsequent virulent simian immunodeficiency virus challenge. The protective vaccine elicited unconventional CD8 T cell responses that were entirely restricted by MHC II or the nonclassical MHC I molecule, MHC-E. These unconventional responses were only elicited by a fibroblast-adapted rhesus CMV vector with limited tissue tropism; a repaired vector with normal tropism elicited conventional responses. Testing whether these unusual protective CD8 T responses could be elicited in humans requires vaccinating human subjects with a fibroblast-adapted mutant of human CMV (HCMV). In this study, we describe the CD8 T cell responses of human subjects vaccinated with two fibroblast-adapted HCMV vaccines. Most responses were identified as conventional classically MHC I restricted, and we found no evidence for MHC II or HLA-E restriction. These results indicate that fibroblast adaptation alone is unlikely to explain the unconventional responses observed in macaques.